A trial of RVT-103 for the treatment Alzheimer's disease and Lewy-body dementia.

Trial Profile

A trial of RVT-103 for the treatment Alzheimer's disease and Lewy-body dementia.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs Donepezil (Primary) ; Donepezil/glycopyrrolate (Primary) ; Glycopyrrolate (Primary) ; Trospium chloride (Primary)
  • Indications Alzheimer's disease; Dementia
  • Focus Adverse reactions; Pharmacokinetics; Proof of concept
  • Most Recent Events

    • 20 Jul 2017 Trial design presented at the Alzheimer's Association International Conference 2017
    • 13 Jun 2017 Results published in an Axovant Sciences Media Release
    • 13 Jun 2017 According to an Axovant Sciences media release, the company is planning a RVT-104 proof of concept study (see profile 285954) based on data from this trial. This trial measured subject nausea in 48 healthy, elderly subjects.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top